The Exploration of Protein Therapies for the Alzheimers Disease
DOI:
https://doi.org/10.61173/fct6xj88Keywords:
AD, cholesterol, APOE, protein therapyAbstract
Alzheimer’s disease (AD) is a global puzzle that first appeared in 1901, the number of patients with AD is soaring all over the world these years. While various mechanisms were proposed, such as Aβ cascade hypothesis, the results were still dissatisfactory, and they all seem to be implicated in each other. Until now, only two kinds of medicines are allowed to treat AD by the FDA, but they are not capable of achieving therapeutic effects. New attention is paid to the treatment options for lipids. This paper analyzes references about cholesterol homeostasis and transport in the brain, finding that an excellent curative effect can emerge by intraperitoneal injection of CS-6253 to raise the level of lipidation of APOE 4, which can provide the references on protein therapies and lipids mechanism for AD, promoting the proceeding of AD study. Nevertheless, the topic that make CS-6253 cross the BBB and perform effectively in the human body have not been tackled, further studies can be biased toward this aspect.
References
[1] Li X, Feng X, Sun X, Hou N, Han F, Liu Y. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990-2019. Front Aging Neurosci, 2022, 14: 937486.
[2] Breijyeh Z, Karaman R. Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules, 2020, 25(24): 5789.
[3] Lanfranco MF, Ng CA, Rebeck GW. ApoE Lipidation as a Therapeutic Target in Alzheimer’s Disease. Int J Mol Sci, 2020, 21(17): 6336.
[4] Akyol O, Akyol S, Chou MC, et al. Lipids and lipoproteins may play a role in the neuropathology of Alzheimer’s disease. Front Neurosci, 2023, 17: 1275932.
[5] Valencia-Olvera AC, Balu D, Bellur S, et al. A novel apoE- mimetic increases brain apoE levels, reduces Aβ pathology and improves memory when treated before onset of pathology in male mice that express APOE3. Alzheimers Res Ther, 2023, 15(1): 216.
[6] Lewandowski CT, Laham MS, Thatcher GRJ. Remembering your A, B, C’s: Alzheimer’s disease and ABCA1. Acta Pharm Sin B, 2022, 12(3): 995-1018.
[7] Björkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol, 2004, 24(5): 806-815.
[8] Kao YC, Ho PC, Tu YK, et al. Lipids and Alzheimer’s Disease. Int J Mol Sci, 2020, 21(4): 1505.
[9] Miao G, Zhuo D, Han X, et al. From degenerative disease to malignant tumors: Insight to the function of ApoE. Biomed Pharmacother, 2023, 158: 114127.
[10] Raulin AC, Doss SV, Trottier ZA, Ikezu TC, Bu G, Liu CC. ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies. Mol Neurodegener, 2022, 17(1): 72.
[11] Chen Q, Wang T, Kang D, Chen L. Protective effect of apolipoprotein E epsilon 3 on sporadic Alzheimer’s disease in the Chinese population: a meta-analysis. Sci Rep, 2022, 12(1): 13620.
[12] Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol, 2021, 20(2): e2.
[13] Jackson RJ, Meltzer JC, Nguyen H, et al. APOE4 derived from astrocytes leads to blood-brain barrier impairment. Brain, 2022, 145(10): 3582-3593.
[14] Chang TY, Yamauchi Y, Hasan MT, Chang C. Cellular cholesterol homeostasis and Alzheimer’s disease. J Lipid Res, 2017, 58(12): 2239-2254.
[15] Victor MB, Leary N, Luna X, et al. Lipid accumulation induced by APOE4 impairs microglial surveillance of neuronalnetwork activity. Cell Stem Cell, 2022, 29(8): 1197-1212.e8.
[16] Chen L, Zhao ZW, Zeng PH, Zhou YJ, Yin WJ. Molecular mechanisms for ABCA1-mediated cholesterol efflux. Cell Cycle, 2022, 21(11): 1121-1139.
[17] Bielicki JK. ABCA1 agonist peptides for the treatment of disease. Curr Opin Lipidol, 2016, 27(1): 40-46.
[18] Valencia-Olvera AC, Balu D, Bellur S, et al. A novel apoE- Dean&Francis mimetic increases brain apoE levels, reduces Aβ pathology and improves memory when treated before onset of pathology in male mice that express APOE3. Alzheimers Res Ther, 2023, 15(1): 216.
[19] Hafiane A, Bielicki JK, Johansson JO, Genest J. Novel Apo E-Derived ABCA1 Agonist Peptide (CS-6253) Promotes Reverse Cholesterol Transport and Induces Formation of preβ-1 HDL In Vitro. PLoS One, 2015, 10(7): e0131997.
[20] Noveir SD, Kerman BE, Xian H, et al. Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys. Alzheimers Res Ther, 2022, 14(1): 87.
[21] Liao F, Hori Y, Hudry E, et al. Anti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis. J Neurosci, 2014, 34(21): 7281-7292.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
